186 related articles for article (PubMed ID: 33746733)
1. Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.
Dakterzada F; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Piñol-Ripoll G
Front Aging Neurosci; 2021; 13():604119. PubMed ID: 33746733
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
4. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
[TBL] [Abstract][Full Text] [Related]
5. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.
Campbell MR; Ashrafzadeh-Kian S; Petersen RC; Mielke MM; Syrjanen JA; van Harten AC; Lowe VJ; Jack CR; Bornhorst JA; Algeciras-Schimnich A
Alzheimers Dement (Amst); 2021; 13(1):e12190. PubMed ID: 34027020
[TBL] [Abstract][Full Text] [Related]
6. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms.
Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812
[TBL] [Abstract][Full Text] [Related]
8. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
Alzheimers Dement (Amst); 2021; 13(1):e12131. PubMed ID: 33598527
[TBL] [Abstract][Full Text] [Related]
9. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.
Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T
J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250
[TBL] [Abstract][Full Text] [Related]
10. Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
Keshavan A; Wellington H; Chen Z; Khatun A; Chapman M; Hart M; Cash DM; Coath W; Parker TD; Buchanan SM; Keuss SE; Harris MJ; Murray-Smith H; Heslegrave A; Fox NC; Zetterberg H; Schott JM
Alzheimers Dement (Amst); 2020; 12(1):e12097. PubMed ID: 32999915
[TBL] [Abstract][Full Text] [Related]
11. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.
Willemse EAJ; Tijms BM; van Berckel BNM; Le Bastard N; van der Flier WM; Scheltens P; Teunissen CE
Alzheimers Dement (Amst); 2021; 13(1):e12182. PubMed ID: 33969174
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.
Willemse EAJ; van Maurik IS; Tijms BM; Bouwman FH; Franke A; Hubeek I; Boelaarts L; Claus JJ; Korf ESC; van Marum RJ; Roks G; Schoonenboom N; Verwey N; Zwan MD; Wahl S; van der Flier WM; Teunissen CE
Alzheimers Dement (Amst); 2018; 10():563-572. PubMed ID: 30406175
[TBL] [Abstract][Full Text] [Related]
13. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
[TBL] [Abstract][Full Text] [Related]
14. Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
Bellomo G; Cataldi S; Paciotti S; Paolini Paoletti F; Chiasserini D; Parnetti L
Alzheimers Res Ther; 2020 Sep; 12(1):121. PubMed ID: 32993776
[TBL] [Abstract][Full Text] [Related]
15. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.
Amft M; Ortner M; Eichenlaub U; Goldhardt O; Diehl-Schmid J; Hedderich DM; Yakushev I; Grimmer T
Alzheimers Res Ther; 2022 Apr; 14(1):60. PubMed ID: 35473631
[TBL] [Abstract][Full Text] [Related]
16. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.
Gobom J; Parnetti L; Rosa-Neto P; Vyhnalek M; Gauthier S; Cataldi S; Lerch O; Laczo J; Cechova K; Clarin M; Benet AL; Pascoal TA; Rahmouni N; Vandijck M; Huyck E; Le Bastard N; Stevenson J; Chamoun M; Alcolea D; Lleó A; Andreasson U; Verbeek MM; Bellomo G; Rinaldi R; Ashton NJ; Zetterberg H; Sheardova K; Hort J; Blennow K
Clin Chem Lab Med; 2022 Jan; 60(2):207-219. PubMed ID: 34773730
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review.
Kurihara M; Kondo S; Ohse K; Nojima H; Kikkawa-Saito E; Iwata A
J Alzheimers Dis; 2024; 99(3):1077-1092. PubMed ID: 38759016
[TBL] [Abstract][Full Text] [Related]
18. The CORCOBIA study: Cut-off points of Alzheimer's disease CSF biomarkers in a clinical cohort.
Puig-Pijoan A; García-Escobar G; Fernández-Lebrero A; Manero-Borràs RM; Sánchez-Benavides G; Navalpotro-Gómez I; Cascales Lahoz D; Suárez-Calvet M; Grau-Rivera O; Boltes Alandí A; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas D; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Peña-Casanova J; Roquer J; Padrós Fluvià A; Puente-Périz V
Neurologia (Engl Ed); 2022 Aug; ():. PubMed ID: 35961506
[TBL] [Abstract][Full Text] [Related]
19. Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.
Shaw LM; Hansson O; Manuilova E; Masters CL; Doecke JD; Li QX; Rutz S; Widmann M; Leinenbach A; Blennow K
Clin Biochem; 2019 Oct; 72():7-14. PubMed ID: 31129181
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis.
Paciotti S; Sepe FN; Eusebi P; Farotti L; Cataldi S; Gatticchi L; Parnetti L
Clin Chim Acta; 2019 Jul; 494():74-78. PubMed ID: 30878539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
